Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Achim A. Jungbluth is active.

Publication


Featured researches published by Achim A. Jungbluth.


Nature Reviews Cancer | 2005

Cancer/testis antigens, gametogenesis and cancer

Andrew J.G. Simpson; Otavia L. Caballero; Achim A. Jungbluth; Yao-Tseng Chen; Lloyd J. Old

Cancer/testis (CT) antigens, of which more than 40 have now been identified, are encoded by genes that are normally expressed only in the human germ line, but are also expressed in various tumour types, including melanoma, and carcinomas of the bladder, lung and liver. These immunogenic proteins are being vigorously pursued as targets for therapeutic cancer vaccines. CT antigens are also being evaluated for their role in oncogenesis — recapitulation of portions of the germline gene-expression programme might contribute characteristic features to the neoplastic phenotype, including immortality, invasiveness, immune evasion, hypomethylation and metastatic capacity.


The New England Journal of Medicine | 2012

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

Michael A. Postow; Margaret K. Callahan; Christopher A. Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A. Jungbluth; Ramon Chua; Arvin Yang; Ruth Ann Roman; Samuel Rosner; Brenna Benson; James P. Allison; Alexander M. Lesokhin; Sacha Gnjatic; Jedd D. Wolchok

The abscopal effect is a phenomenon in which local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site. The abscopal effect may be mediated by activation of the immune system. Ipilimumab is a monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage with antibody responses to the cancer-testis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibody responses to other antigens after radiotherapy. (Funded by the National Institutes of Health and others.).


Immunological Reviews | 2002

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

Matthew J. Scanlan; Ali Gure; Achim A. Jungbluth; Lloyd J. Old; Yao-Tseng Chen

Summary: Cancer/testis (CT) antigens are a category of tumor antigens with normal expression restricted to male germ cells in the testis but not in adult somatic tissues. In some cases, CT antigens are also expressed in ovary and in trophoblast. In malignancy, this gene regulation is disrupted, resulting in CT antigen expression in a proportion of tumors of various types. Since their initial identification by T‐cell epitope cloning, the list of CT antigens has been greatly expanded through serological expression cloning (SEREX) and differential mRNA expression analysis, and approximately 20 CT antigens or antigen families have been identified to date. Characteristics commonly shared by CT antigens, aside from the highly tissue‐restricted expression profile, include existence as multigene families, frequent mapping to chromosome X, heterogeneous protein expression in cancer, likely correlation with tumor progression, induction of expression by hypomethylation and/or histone acetylation, and immunogenicity in cancer patients. Spontaneous humoral and cell‐mediated immune responses have been demonstrated against several CT antigens, including NY‐ESO‐1, MAGE‐A, and SSX antigens. Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen‐specific cancer vaccines, and clinical trials with MAGE‐A and NY‐ESO‐1 are in progress.


The New England Journal of Medicine | 2008

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

Naomi N. Hunder; Herschel Wallen; Jianhong Cao; Deborah W. Hendricks; John Z. Reilly; Rebecca Rodmyre; Achim A. Jungbluth; Sacha Gnjatic; John A. Thompson; Cassian Yee

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.


International Journal of Cancer | 2001

Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

Achim A. Jungbluth; Yao-Tseng Chen; Elisabeth Stockert; Denise Kolb; Kristin Iversen; Keren Coplan; Barbara Williamson; Nasser K. Altorki; Lloyd J. Old

NY‐ESO‐1, a member of the CT (cancer/testis) family of antigens, is expressed in normal testis and in a range of human tumor types. Knowledge of NY‐ESO‐1 expression has depended on RT‐PCR detection of mRNA and there is a need for detecting NY‐ESO‐1 at the protein level. In the present study, a method for the immunochemical detection of NY‐ESO‐1 in paraffin‐embedded tissues has been developed and used to define the expression pattern of NY‐ESO‐1 in normal tissues and in a panel of human tumors. No normal tissue other than testis showed NY‐ESO‐1 reactivity, and expression in testis was restricted to germ cells particularly spermatogonia. In human tumors, the frequency of NY‐ESO‐1 antigen expression corresponds with past analysis of NY‐ESO‐1 mRNA expression e.g., 20–30% of lung cancers, bladder cancers and melanoma, and no expression in colon and renal cancer. Co‐typing of NY‐ESO‐1 antigen and mRNA expression in a large panel of lung cancers showed a good correlation. There is great variability in NY‐ESO‐1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression.


Lancet Oncology | 2007

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial

Chaitanya R. Divgi; Neeta Pandit-Taskar; Achim A. Jungbluth; Victor E. Reuter; Mithat Gonen; Shutian Ruan; Christine Pierre; Andrew Nagel; D. A. Pryma; John L. Humm; Steven M. Larson; Lloyd J. Old; Paul Russo

BACKGROUND Preoperative identification of tumour type could have important implications for the choice of treatment for renal cancers. Antibody cG250 reacts against carbonic anhydrase-IX, which is over-expressed in clear-cell renal carcinomas. We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour. METHODS 26 patients with renal masses who were scheduled to undergo surgical resection by laparotomy received a single intravenous infusion of 185 MBq/10 mg of (124)I-cG250 over 20 min in this open-label pilot study. Surgery was scheduled 1 week after (124)I-cG250 infusion. PET and CT scanning of the abdomen, including the kidneys, within 3 h before surgery was planned for all patients. The obtained images were graded as positive (defined as a tumour-to-healthy-kidney ratio >3 to 1) or negative for antibody uptake, and the surgeon was informed of the scan results before surgery. After surgery, resected tumours were histopathologically classified as clear-cell renal carcinoma or otherwise. The trial is registered on the clinical trials site of the National Cancer Institute website http://clinicaltrials.gov/ct/show/NCT00199888. FINDINGS One patient received inactive antibody and was excluded from analysis. 15 of 16 clear-cell carcinomas were identified accurately by antibody PET, and all nine non-clear-cell renal masses were negative for the tracer. The sensitivity of (124)I-cG250 PET for clear-cell kidney carcinoma in this trial was 94% (95% CI 70-100%); the negative predictive value was 90% (55-100%), and specificity and positive predictive accuracy were both 100% (66-100% and 78-100%, respectively). INTERPRETATION PET with (124)I-cG250 can identify accurately clear-cell renal carcinoma; a negative scan is highly predictive of a less aggressive phenotype. Stratification of patients with renal masses by (124)I-cG250 PET can identify aggressive tumours and help decide treatment.


Proceedings of the National Academy of Sciences of the United States of America | 2008

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F. Gallardo; Erika Ritter; Geoffrey Y. Ku; Achim A. Jungbluth; Neil Howard Segal; Teresa Rasalan; Gregor Manukian; Yinyan Xu; Ruth Ann Roman; Stephanie L. Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; L J Old; James P. Allison; Jedd D. Wolchok

Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell responses and induce durable clinical responses in patients with metastatic melanoma. The functional impact of anti-CTLA-4 therapy on human immune responses is still unclear. To explore this, we analyzed immune-related adverse events and immune responses in metastatic melanoma patients treated with ipilimumab, a fully human anti-CTLA-4 monoclonal antibody. Fifteen patients were selected on the basis of availability of suitable specimens for immunologic monitoring, and eight of these showed evidence of clinical benefit. Five of the eight patients with evidence of clinical benefit had NY-ESO-1 antibody, whereas none of seven clinical non-responders was seropositive for NY-ESO-1. All five NY-ESO-1 seropositive patients had clearly detectable CD4+ and CD8+ T cells against NY-ESO-1 following treatment with ipilimumab. One NY-ESO-1 seronegative clinical responder also had a NY-ESO-1 CD4+ and CD8+ T cell response, possibly related to prior vaccination with NY-ESO-1. Among five clinical non-responders analyzed, only one had a NY-ESO-1 CD4+ T cell response and this patient did not have detectable anti-NY-ESO-1 antibody. Overall, NY-ESO-1-specific T cell responses increased in frequency and functionality during anti-CTLA-4 treatment, revealing a polyfunctional response pattern of IFN-γ, MIP-1β and TNF-α. We therefore suggest that CTLA-4 blockade enhanced NY-ESO-1 antigen-specific B cell and T cell immune responses in patients with durable objective clinical responses and stable disease. These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade.


Advances in Cancer Research | 2006

NY-ESO-1: review of an immunogenic tumor antigen.

Sacha Gnjatic; Hiroyoshi Nishikawa; Achim A. Jungbluth; Ali O. Gure; Gerd Ritter; Elke Jäger; Alexander Knuth; Yao-Tseng Chen; Lloyd J. Old

In the 9 years since its discovery, cancer-testis antigen NY-ESO-1 has made one of the fastest transitions from molecular, cellular, and immunological description to vaccine and immunotherapy candidate, already tested in various formulations in more than 30 clinical trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of cancer patients. An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here.


Proceedings of the National Academy of Sciences of the United States of America | 2007

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

Danila Valmori; Naira E. Souleimanian; Valeria Tosello; Nina Bhardwaj; Sylvia Adams; David O'Neill; Anna C. Pavlick; Juliet Escalon; Crystal M. Cruz; Angelica Angiulli; Francesca Angiulli; Gregory Mears; Susan M. Vogel; Linda Pan; Achim A. Jungbluth; Eric Hoffmann; Ralph Venhaus; Gerd Ritter; Lloyd J. Old; Maha Ayyoub

The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8+ T cell responses, through in vivo cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4+ Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8+ T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote in vitro cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8+ T cells, indicated that elicitation of NY-ESO-1-specific CD8+ T cell responses by cross-priming in vivo was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of in vivo cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Jianda Yuan; Matthew Adamow; Brian A. Ginsberg; Teresa Rasalan; Erika Ritter; Humilidad F. Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L. Terzulli; Deborah Kuk; Katherine S. Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A. Jungbluth; James P. Allison; Lloyd J. Old; Jedd D. Wolchok; Sacha Gnjatic

Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients with melanoma. To characterize the association between immune response and clinical outcome, we first analyzed NY-ESO-1 serum antibody by ELISA in 144 ipilimumab-treated patients with melanoma and found 22 of 140 (16%) seropositive at baseline and 31 of 144 (22%) seropositive following treatment. These NY-ESO-1–seropositive patients had a greater likelihood of experiencing clinical benefit 24 wk after ipilimumab treatment than NY-ESO-1–seronegative patients (P = 0.02, relative risk = 1.8, two-tailed Fisher test). To understand why some patients with NY-ESO-1 antibody failed to experience clinical benefit, we analyzed NY-ESO-1–specific CD4+ and CD8+ T-cell responses by intracellular multicytokine staining in 20 NY-ESO-1–seropositive patients and found a surprising dissociation between NY-ESO-1 antibody and CD8 responses in some patients. NY-ESO-1–seropositive patients with associated CD8+ T cells experienced more frequent clinical benefit (10 of 13; 77%) than those with undetectable CD8+ T-cell response (one of seven; 14%; P = 0.02; relative risk = 5.4, two-tailed Fisher test), as well as a significant survival advantage (P = 0.01; hazard ratio = 0.2, time-dependent Cox model). Together, our data suggest that integrated NY-ESO-1 immune responses may have predictive value for ipilimumab treatment and argue for prospective studies in patients with established NY-ESO-1 immunity. The current findings provide a strong rationale for the clinical use of modulators of immunosuppression with concurrent approaches to favor tumor antigen-specific immune responses, such as vaccines or adoptive transfer, in patients with cancer.

Collaboration


Dive into the Achim A. Jungbluth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sacha Gnjatic

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yao-Tseng Chen

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Elisabeth Stockert

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Denise Frosina

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Kristin Iversen

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Barbara Williamson

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Erika Ritter

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Keren Coplan

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge